#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cerebral amyloid angiopathy Gaucher's disease type I Polymyositis Autologous haematopoietic stem cell transplant Cutaneous T-cell lymphoma Myxoid liposarcoma Parkinson's disease Hypertriglyceridaemia Malignant melanoma Non-renal cell carcinoma of kidney Huntington's disease Plasma cell myeloma Lip and/or oral cavity cancer Hairy cell leukaemia Hypersensitivity pneumonitis More trials…

    Learn about Rare Diseases

    Mast cell activation syndrome – Life with Disease Pituitary-dependent Cushing’s syndrome – Diagnostics Marfan’s syndrome – Trials in Disease Fragile X syndrome – Diagnostics Ehlers-Danlos syndrome – Treatment Uterine leiomyosarcoma – Treatment Fabry’s disease – Basic Information Breast angiosarcoma Waldenstrom’s macroglobulinaemia – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Iomeprol Clioquinol Alirocumab Mps-102 Enfortumab Vedotin Vonicog Alfa LTG-001 Xtmab-16 Sulfasalazine Povidone Pyrazinamide L-Histidine Hydrochloride F125/10 At-1501 Pehero Afamitresgene Autoleucel TAGRAXOFUSP YL201 Lysine Acetate VTX2735 SODIUM More therapies…

    Learn about Your Condition

    Craniotomy Aphthous ulcer Ulcerative keratitis Infant sedation Bile duct adenocarcinoma Cortisol abnormal Post procedural swelling Bronchopulmonary aspergillosis Arthroscopy Factor IX deficiency Procedural headache Eclampsia Small intestine adenocarcinoma Astrocytoma malignant Osteoarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Università degli studi Gabriele D’Annunzio Chieti-Pescara…

Università degli studi Gabriele D’Annunzio Chieti-Pescara Centro di Studi e tecnologie avanzate

Via Luigi Polacchi 11, Chieti, 66100, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Sonelokimab
    Belgium Bulgaria Czechia France Germany Hungary +7

  • Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rocatinlimab
    Croatia Czechia Germany Greece Hungary Italy +6

  • Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

    Not recruiting

    3 1
    Investigated Drugs:
    • Maridebart Cafraglutide
    Bulgaria Czechia Germany Hungary Italy Poland

  • Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

    Not recruiting

    3 1
    Investigated Drugs:
    • Finerenone
    Denmark Germany Italy Spain

  • Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +12

  • Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Bulgaria France Germany Italy The Netherlands +1

  • Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Frexalimab
    Belgium Bulgaria Czechia France Germany Greece +7

  • Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Chronic kidney disease
    • Type 2 diabetes mellitus
    • Obesity
    Investigated Drugs:
    • Semaglutide
    Bulgaria Italy Poland Spain

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Embolism venous
    Investigated Drugs:
    • Abelacimab
    • Apixaban
    Austria Czechia France Germany Hungary Ireland +6
Previous Page
1 … 3 4 5 6 7 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!